Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats

Journal of Pharmacological Sciences

Volumn 122, Issue 2, 2013, Pages 103-108

  Ohnishi, Keisuke ^a   Murase, Miki ^a   Nakano, Daisuke ^a   Pelisch, Nicolas ^a   Hitomi, Hirofumi ^a   Kobori, Hiroyuki ^a   Morimoto, Satoshi ^b   Mori, Hirohito ^a   Masaki, Tsutomu ^a   Ohmori, Koji ^a   Kohno, Masakazu ^a   Ichihara, Atsuhiro ^b   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Angiotensin converting enzyme (ACE) inhibitor; Kidney

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLMESARTAN; TEMOCAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HYPERTENSION; INFUSION; MALE; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE LEVEL; TREATMENT DURATION;

EID: 84880787544     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13045FP     Document Type: Article

References (41)

1. Wilson PW. Established risk factors and coronary artery disease: the framingham study. Am J Hypertens. 1994;7:7S-12S.
2. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595-601.
3. Mori T, Ogawa S, Cowely AW Jr, Ito S. Role of renal medullary oxidative and/or carbonyl stress in salt-sensitive hypertension and diabetes. Clin Exp Pharmacol Physiol. 2012;39:125-131.
4. Oki K, Gomez-Sanchez EP, Gomez-Sanchez CE. Role of mineralocorticoid action in the brain in salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2012;39:90-95.
5. 1-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in dahl salt-sensitive rats. J Pharmacol Sci. 2013; 121:95-102.
6. Wang CT, Chin SY, Navar LG. Impairment of pressure-natriuresis and renal autoregulation in ang ii-infused hypertensive rats. Am J Physiol Renal Physiol. 2000;279:F319-F325.
7. Kittikulsuth W, Pollock JS, Pollock DM. Loss of renal medullary endothelin b receptor function during salt deprivation is regulated by angiotensin ii. Am J Physiol Renal Physiol. 2012;303: F659-F666.
8. Kitada K, Nakano D, Hitomi H, Kobori H, Deguchi K, Mori H, et al. Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor-alpha in human proximal tubular cells. Clin Exp Pharmacol Physiol. 2012; 39:858-863.
9. Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, et al. Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in dahl salt-sensitive rats. PLoS One. 2012;7:e41896.
10. Huang Y, Yamamoto T, Misaki T, Suzuki H, Togawa A, Ohashi N, et al. Enhanced intrarenal receptor-mediated prorenin activation in chronic progressive anti-thymocyte serum nephritis rats on high salt intake. Am J Physiol Renal Physiol. 2012;303: F130-F138.
11. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59: 251-287.
12. Shao W, Seth DM, Navar LG. Angiotensin ii type 1 receptor-mediated augmentation of urinary excretion of endogenous angiotensin ii in val5-angiotensin ii-infused rats. Hypertension. 2010;56:378-383.
13. Gonzalez-Villalobos RA, Billet S, Kim C, Satou R, Fuchs S, Bernstein KE, et al. Intrarenal angiotensin-converting enzyme induces hypertension in response to angiotensin i infusion. J Am Soc Nephrol. 2011;22:449-459.
14. Zou JX, Luciw PA. The transcriptional transactivator of simian foamy virus 1 binds to a DNA target element in the viral internal promoter. Proc Natl Acad Sci U S A. 1996;93:326-330.
15. Zhuo JL, Imig JD, Hammond TG, Orengo S, Benes E, Navar LG. Ang ii accumulation in rat renal endosomes during ang ii-induced hypertension: Role of at(1) receptor. Hypertension. 2002;39:116-121.
16. Zou LX, Imig JD, von Thun AM, Hymel A, Ono H, Navar LG. Receptor-mediated intrarenal angiotensin ii augmentation in angiotensin ii-infused rats. Hypertension. 1996;28:669-677.
17. Zou LX, Imig JD, Hymel A, Navar LG. Renal uptake of circulating angiotensin ii in val5-angiotensin ii infused rats is mediated by at1 receptor. Am J Hypertens. 1998;11:570-578.
18. Fan YY, Nishiyama A, Fujisawa Y, Kobori H, Nakano D, Matsuura J, et al. Contribution of chymase-dependent angio-tensin ii formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters. J Pharmacol Sci. 2009;111: 82-90.
19. Ingelfinger JR. Selective, isolated proximal tubular angio-tensinogen overexpression and salt-sensitive hypertension. Am J Hypertens. 2012;25:628.
20. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins i and ii in anesthetized rats. Hypertension. 2002;39:129-134.
21. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger GA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 1995;92:1387-1388.
22. Shibahara H, Kamata M, Hu J, Nakagawa H, Obara H, Kondoh N, et al. Activity of testis angiotensin converting enzyme (ace) in ejaculated human spermatozoa. Int J Androl. 2001;24:295-299.
23. Lei B, Nakano D, Fujisawa Y, Liu Y, Hitomi H, Kobori H, et al. N-type calcium channel inhibition with cilnidipine elicits glo-merular podocyte protection independent of sympathetic nerve inhibition. J Pharmacol Sci. 2012;119:359-367.
24. Nakano D, Kobori H, Burford JL, Gevorgyan H, Seidel S, Hitomi H, et al. Multiphoton imaging of the glomerular permeability of angiotensinogen. J Am Soc Nephrol. 2012;23:1847-1856.
25. Pfeifer CA, Suzuki F, Jackson EK. Selective a1 adenosine receptor antagonism augments beta-adrenergic-induced renin release in vivo. Am J Physiol. 1995;269:F469-F479.
26. van Kats JP, de Lannoy LM, Jan Danser AH, van Meegen JR, Verdouw PD, Schalekamp MA. Angiotensin ii type 1 (at1) receptor-mediated accumulation of angiotensin ii in tissues and its intracellular half-life in vivo. Hypertension. 1997;30:42-49.
27. Kobori H, Prieto-Carrasquero MC, Ozawa Y, Navar LG. At1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin ii-dependent hypertension. Hypertension. 2004;43: 1126-1132.
28. Nishiyama A, Yoshizumi M, Rahman M, Kobori H, Seth DM, Miyatake A, et al. Effects of at1 receptor blockade on renal injury and mitogen-activated protein activity in dahl salt-sensitive rats. Kidney Int. 2004;65:972-981.
29. Lei B, Nakano D, Fan YY, Kitada K, Hitomi H, Kobori H, et al. Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan. J Pharmacol Sci. 2012;119:131-138.
30. Ihara G, Kiyomoto H, Kobori H, Nagai Y, Ohashi N, Hitomi H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin ii blockade. J Hypertens. 2010;28:2289-2298.
31. Sofue T, Kiyomoto H, Kobori H, Urushihara M, Nishijima Y, Kaifu K, et al. Early treatment with olmesartan prevents juxta-medullary glomerular podocyte injury and the onset of micro-albuminuria in type 2 diabetic rats. Am J Hypertens. 2012;25: 604-611.
32. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation. 2012;125:1402-1413.
33. Gonzalez-Villalobos RA, Satou R, Seth DM, Semprun-Prieto LC, Katsurada A, Kobori H, et al. Angiotensin-converting enzyme-derived angiotensin ii formation during angiotensin ii-induced hypertension. Hypertension. 2009;53:351-355.
34. Kakimoto K, Takai S, Murano M, Ishida K, Yoda Y, Inoue T, et al. Significance of chymase-dependent matrix metallo-proteinase-9 activation on indomethacin-induced small intestinal damages in rats. J Pharmacol Exp Ther. 2010;332:684-689.
35. Kanemitsu H, Takai S, Tsuneyoshi H, Nishina T, Yoshikawa K, Miyazaki M, et al. Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res. 2006;29:57-64.
36. Ahmad S, Varagic J, Westwood BM, Chappell MC, Ferrario CM. Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One. 2011;6:e15759.
37. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin ii from angiotensin-(1-12) in human atrial tissue. PLoS One. 2011;6:e28501.
38. Liu W, Chen J, Xu T, Tian W, Li Y, Zhang Z, et al. Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase. Am J Hypertens. 2012;25:250-260.
39. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, et al. Angiotensin ii causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103:17985-17990.
40. Ramkumar N, Stuart D, Ying J, Kohan DE. A possible interaction between systemic and renal angiotensinogen in the control of blood pressure. Am J Hypertens. 2013;26:473-480.
41. Ibrahim HN, Jackson S, Connaire J, Matas A, Ney A, Najafian B, et al. Angiotensin ii blockade in kidney transplant recipients. J Am Soc Nephrol. 2013;24:320-327.